An FDA advisory committee has recommended against the use of Avastin in breast cancer treatment. The decision was based upon new drug trials that demonstrated no demonstrable benefit in the treatment of breast cancer.
The recommendation is a set back for those who believed Avastin would prevent the disease’s progression. The FDA should make a final decision by Sept. 17. It is not required to follow the recommendations of advisory panels, but generally does.
Latest posts by Eva Bleich (see all)
- Federal Judge Finds Health Insurer DiscriminatedAgainst Patients with Substance Abuse and Mental Health Disorders - March 25, 2019
- Factors Impacting Maternal Health During Hospital Births - March 22, 2019
- Jury Awards $117 million in Johnson & Johnson’sFirst Trial Loss in Asbestos-Related, Talc Powder Lawsuits - April 24, 2018